By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […]
By Tuyen Ong, CEO Ring Therapeutics, CEO-Partner Flagship Pioneering Gene therapy is a life-changing class of medicine that can treat patients with once intractable diseases. While revolutionary, significant limitations remain for the vectors that carry them. Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, […]
A recent study explains how researchers have devised a new method for delivering particles into stem cells, which are difficult to penetrate. The discovery will make it easier to direct and enhance the processes involved in regenerative medicine. Regenerative medicine takes advantage of the fact that our body’s stem cells can change into many other […]
Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […]
Nanite Inc. has announced an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung. This builds on the $6 million seed financing recently announced by the company. One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug […]
Flagship Pioneering has created Ampersand Biomedicines, a company creating programmable medicines that are intended to be safer, more tolerable, and effective by acting at the site of disease. Flagship Pioneering has initially committed $50 million to advance the company’s Address, Navigate, Design (AND) platform and develop an initial pipeline of medicines across a range of […]
Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective at knocking down expression of a target protein. Gene therapy is a potential mode of treatment for a wide variety of diseases caused by genetic mutations. While it has been an area of diverse and […]
A research team from LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed thyroid hormone (TH) – encapsulated nanoparticles modified with adipose-homing peptide, which selectively transport TH to adipose tissues. The researchers say this will advance the treatment of obesity-related medical complications with TH by overcoming its severe adverse effects caused by […]
Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life Science through its TVM Life Science Innovation II SCSp fund. Recurv Pharma plans to develop a novel taxane therapy to treat solid tumors to the proof-of-concept stage. The U.S. based biotech firm is the eighth early-stage or project-focused company (PFC) […]
Sensorion and EVEON are collaborating on the design and development of an injection system for the delivery of Sensorion’s gene therapy products to the inner ear. Therapies for treating genetic hearing loss are often challenging due to the need for delivery into the inner ear, a very small and delicate organ embedded in the temporal […]
A new study by the University of Barcelona in Spain has analyzed the viability of a new nanomolecule that can be used as a nanotransporter to deliver drugs. The results, published in the journal Colloids and Surfaces B: Biointerfaces, show that liposomes designed by researchers are able to transport and deliver an anticancer drug that […]